Mirum will now await results from its second Phase III HDV study on brelovitug Mirum Pharmaceuticals has secured a positive outcome for the first late-stage trial on its chronic hepatitis delta virus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results